Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes: [[:Category:Third-generation neuroleptics|Third-generation neuroleptic]]

& fda max: 30 mg/day (adult schizophrenia); 15 mg/day (MDD adjunct)

Use the filters below to narrow your results.

Aripiprazole (1)

Abilify (oral), Abilify Maintena (monthly IM LAI), Aristada (aripiprazole lauroxil IM LAI), Abilify Asimtufii (bi-monthly IM LAI), Abilify MyCite (digital ingestion sensor) (1)

None (1)

'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' (1)

Schizophrenia/bipolar mania: 10-15 mg PO once daily, target 15-30 mg. MDD adjunct: 2-5 mg/day, target 5-15 mg. Pediatric autism irritability: 2 mg, titrate to 5-15 mg. Maintena LAI: 400 mg IM every 4 weeks after oral overlap (1)

Tablets 2, 5, 10, 15, 20, 30 mg; ODT 10, 15 mg; oral solution 1 mg/mL; acute IM injection 9.75 mg/1.3 mL; Maintena LAI 300, 400 mg monthly; Aristada LAI 441, 662, 882, 1064 mg (4-8 week dosing); Asimtufii bi-monthly (1)

intramuscular (acute and long-acting) (1) · Oral (1)

Neuroleptic effect emerges over days to weeks; activation symptoms (akathisia, insomnia) often within days (1)

24 hours (oral); 4-8 weeks (LAI) (1)

~75 hours (long, accumulates over weeks)'"`UNIQ--ref-00000023-QINU`"' (1)

~87% (oral)'"`UNIQ--ref-00000024-QINU`"' (1)

Limited human data; signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (1)

Showing below up to 1 result in range #1 to #1.

A

Aripiprazole

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"